Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Gross ProfitOther Operating ExpensesRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mainz Biomed N.V (MYNZ) EBITDA: 2022-2023

Historic EBITDA for Mainz Biomed N.V (MYNZ) over the last 2 years, with Dec 2023 value amounting to $6.0 million.

  • Mainz Biomed N.V's EBITDA rose 171.75% to $6.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $26.8 million, marking a year-over-year increase of 177.35%. This contributed to the annual value of $21.8 million for FY2024, which is 18.82% down from last year.
  • As of Q4 2023, Mainz Biomed N.V's EBITDA stood at $6.0 million, which was up 3.44% from $5.8 million recorded in Q3 2023.
  • Mainz Biomed N.V's 5-year EBITDA high stood at $8.3 million for Q2 2023, and its period low was -$8.4 million during Q4 2022.
  • Over the past 2 years, Mainz Biomed N.V's median EBITDA value was $5.9 million (recorded in 2023), while the average stood at $4.6 million.
  • Data for Mainz Biomed N.V's EBITDA shows a peak YoY spiked of 171.75% (in 2023) over the last 5 years.
  • Mainz Biomed N.V's EBITDA (Quarterly) stood at -$8.4 million in 2022, then surged by 171.75% to $6.0 million in 2023.
  • Its EBITDA was $6.0 million in Q4 2023, compared to $5.8 million in Q3 2023 and $8.3 million in Q2 2023.